270 related articles for article (PubMed ID: 18253072)
1. (18)F-FDG PET versus (18)F-FDG PET/CT for adrenal gland lesion characterization: a comparison of diagnostic efficacy in lung cancer patients.
Sung YM; Lee KS; Kim BT; Choi JY; Chung MJ; Shim YM; Yi CA; Kim TS
Korean J Radiol; 2008; 9(1):19-28. PubMed ID: 18253072
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET/CT in the evaluation of adrenal masses in lung cancer patients.
Lu Y; Xie D; Huang W; Gong H; Yu J
Neoplasma; 2010; 57(2):129-34. PubMed ID: 20099976
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer.
Kumar R; Xiu Y; Yu JQ; Takalkar A; El-Haddad G; Potenta S; Kung J; Zhuang H; Alavi A
J Nucl Med; 2004 Dec; 45(12):2058-62. PubMed ID: 15585482
[TBL] [Abstract][Full Text] [Related]
4. Adrenal nodules at FDG PET/CT in patients known to have or suspected of having lung cancer: a proposal for an efficient diagnostic algorithm.
Brady MJ; Thomas J; Wong TZ; Franklin KM; Ho LM; Paulson EK
Radiology; 2009 Feb; 250(2):523-30. PubMed ID: 19188319
[TBL] [Abstract][Full Text] [Related]
5. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI.
Yun M; Kim W; Alnafisi N; Lacorte L; Jang S; Alavi A
J Nucl Med; 2001 Dec; 42(12):1795-9. PubMed ID: 11752075
[TBL] [Abstract][Full Text] [Related]
7. PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients.
Boland GW; Blake MA; Holalkere NS; Hahn PF
AJR Am J Roentgenol; 2009 Apr; 192(4):956-62. PubMed ID: 19304700
[TBL] [Abstract][Full Text] [Related]
8. Fluorodeoxyglucose-positron-emission tomography/computed tomography imaging for adrenal masses in patients with lung cancer: review and diagnostic algorithm.
Stone WZ; Wymer DC; Canales BK
J Endourol; 2014 Jan; 28(1):104-11. PubMed ID: 23927734
[TBL] [Abstract][Full Text] [Related]
9. The value of adding (18)F-FDG PET/CT to adrenal protocol CT for characterizing adrenal metastasis (≥ 10 mm) in oncologic patients.
Park SY; Park BK; Kim CK
AJR Am J Roentgenol; 2014 Feb; 202(2):W153-60. PubMed ID: 24450697
[TBL] [Abstract][Full Text] [Related]
10. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
[TBL] [Abstract][Full Text] [Related]
12. What parameters from 18F-FDG PET/CT are useful in evaluation of adrenal lesions?
Kunikowska J; Matyskiel R; Toutounchi S; Grabowska-Derlatka L; Koperski L; Królicki L
Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2273-80. PubMed ID: 25027709
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography.
Erasmus JJ; Patz EF; McAdams HP; Murray JG; Herndon J; Coleman RE; Goodman PC
AJR Am J Roentgenol; 1997 May; 168(5):1357-60. PubMed ID: 9129444
[TBL] [Abstract][Full Text] [Related]
14. FDG-PET and CT characterization of adrenal lesions in cancer patients.
Jana S; Zhang T; Milstein DM; Isasi CR; Blaufox MD
Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):29-35. PubMed ID: 16193311
[TBL] [Abstract][Full Text] [Related]
15. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy--initial experience.
Blake MA; Slattery JM; Kalra MK; Halpern EF; Fischman AJ; Mueller PR; Boland GW
Radiology; 2006 Mar; 238(3):970-7. PubMed ID: 16505394
[TBL] [Abstract][Full Text] [Related]
16. Differentiation of an adrenal mass in patients with non-small cell lung cancer by means of a normal range of adrenal standardized uptake values on FDG PET/CT.
Kim BS; Lee JD; Kang WJ
Ann Nucl Med; 2015 Apr; 29(3):276-83. PubMed ID: 25480483
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic accuracy of
Kim SJ; Lee SW; Pak K; Kim IJ; Kim K
Br J Radiol; 2018 Jun; 91(1086):20170520. PubMed ID: 29327944
[TBL] [Abstract][Full Text] [Related]
18. Performance of integrated FDG-PET/CT for differentiating benign and malignant lung lesions--results from a large prospective clinical trial.
Pauls S; Buck AK; Halter G; Mottaghy FM; Muche R; Bluemel C; Gerstner S; Krüger S; Glatting G; Sunder-Plassmann L; Möller P; Brambs HJ; Reske SN
Mol Imaging Biol; 2008; 10(2):121-8. PubMed ID: 18204955
[TBL] [Abstract][Full Text] [Related]
19. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis.
Perri M; Erba P; Volterrani D; Guidoccio F; Lazzeri E; Caramella D; Mariani G
AJR Am J Roentgenol; 2011 Jul; 197(1):209-16. PubMed ID: 21701032
[TBL] [Abstract][Full Text] [Related]
20. Utility of PET/CT in differentiating benign from malignant adrenal nodules in patients with cancer.
Vikram R; Yeung HD; Macapinlac HA; Iyer RB
AJR Am J Roentgenol; 2008 Nov; 191(5):1545-51. PubMed ID: 18941099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
